This is a watershed moment for psychedelic medicine.
Eli Lilly’s acquisition of AtaiBeckley for up to $3.8 billion sends a strong signal that psychedelic therapeutics are moving from the margins toward mainstream pharmaceutical development. The deal centers on BPL-003, an intranasal synthetic 5-MeO-DMT candidate for treatment-resistant depression that is advancing into Phase 3.
But this milestone also raises important questions.
As capital and large pharmaceutical companies enter the space, how do we preserve the principles that many believe are essential to these therapies—patient preparation, appropriate support, integration, ethical access, and responsible use?
Scientific validation and broader access are important. So is ensuring that commercialization doesn’t overshadow the human elements that contribute to safe and effective care.
The future of psychedelic medicine won’t be defined solely by breakthrough molecules. It will also be defined by the systems, ethics, and standards we build around them.
What do you think this means for the future of psychedelic-assisted care?
Originally published on Entheology Project on July 20, 2026. Read the original